Home › Compare › NPKYF vs ABBV
NPKYF yields 4.17% · ABBV yields 3.06%● Live data
📍 NPKYF pulled ahead of the other in Year 4
Combined, NPKYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NPKYF + ABBV for your $10,000?
Nippon Kayaku Co., Ltd., together with its subsidiaries, develops, manufactures, and sells functional chemicals, pharmaceuticals, safety systems, and agrochemicals and other products in Japan and internationally. The company's Functional and Chemical Business segment offers functional materials, such as epoxy resins, UV-curable resins, sealants for LCD and LED, maleimide resins, photoresists and insulating materials for micro electromechanical systems, and cleaning agents and chemicals. This segment also provides color materials, including inkjet colorants, dyes for textiles and papers, and materials for thermal paper; catalysts for the production of acrylic and methacrylic acid; and polarizing films, inorganic polarizers, liquid crystal display components and projector parts, and components for x-ray analysis. Its Pharmaceuticals Business segment offers anti-cancer and cancer-related drugs, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drugs and intermediates of pharmaceuticals, and drugs for diagnosing cancer, as well as GlycoMark, a product as a marker of blood sugar control used for diabetes. The company's Safety Systems Business segment provides airbag inflators, micro gas generators for seatbelt pretensioners, and squibs. Its Agrochemicals Business segment offers agricultural insecticides, herbicides, soil fumigants, and insanitary insecticides. The company also engages in real estate leasing services. The company was formerly known as Nihon Kayaku Seizou Co., Ltd. and changed its name to Nippon Kayaku Co., Ltd. in 1945. Nippon Kayaku Co., Ltd. was incorporated in 1916 and is headquartered in Tokyo, Japan.
Full NPKYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.